Curious about today's AI digest?ai-tldr.dev

Daily Digest

BriefMarket · bullishLow impact
Esc

Novo Nordisk Stock Rises 2.7% After CagriSema Trial Data

PR Newswire (Novo Nordisk)2 min read5 sources

Why is Novo Nordisk stock up today?

Novo Nordisk (NOVO-B.CO) stock rose 2.7% to 286.1 kroner on Monday after trial data showed its CagriSema obesity drug cut weight by about 21%, with a US decision due this quarter.

Key numbers

Weight loss, 1.0 mg dose21.0%vs 2.0% placebo
Weight loss, 1.7 mg dose20.7%vs 2.0% placebo
Novo shares, Copenhagen286.1 DKK+2.7%
Novo shares, US (NVO)NYSE+2.4%
Quit due to side effects2.9%–4.9%vs 4.9% placebo

What happened

Novo Nordisk (NOVO-B.CO) stock rose 2.7% to 286.1 kroner on Monday after trial data showed its CagriSema obesity drug cut weight by about 21%, with a US decision due this quarter. In a 68-week study of 309 adults, the two lower doses led to average weight loss of 20.7% and 21.0%, compared with 2.0% for people given a dummy shot (placebo). Those figures assume patients stayed on treatment. The company's US-listed shares (NVO) rose about 2.4%.

Why it matters

Novo Nordisk needs a strong next-generation weight-loss drug to keep up with Eli Lilly, which has already launched its own obesity pill and just raised its sales forecast. CagriSema combines two medicines that mimic natural appetite-control hormones, and about 21% weight loss is near the top of what drugs in this class have shown. The US decision is expected in the fourth quarter, but that timing is the company's own expectation, not an FDA promise.

Who this affects

Marketbullish
Low impact
Novo shareholders gained modestly; wider market barely moved.
Companybullish
Medium impact
Strong data supports Novo's case for US approval.
Competitorsbearish
Low impact
Eli Lilly faces a tougher rival if CagriSema is approved.
Industrybullish
Medium impact
Obesity drug makers see more choice and competition for patients.

Novo Nordisk vs Eli Lilly, Pfizer, Amgen

Novo NordiskNVO—-19%12x
Eli LillyLLY$1.28T+33%—
PfizerPFE$165B—9.5x
AmgenAMGN$252B——

As of 2026-11-16

How we got here

  1. Novo Nordisk files its US application for CagriSema in obesity.

  2. REDEFINE 9 results presented at ObesityWeek and published in The Lancet Diabetes & Endocrinology.

  3. Novo shares rise 2.7% in Copenhagen; US shares up about 2.4%.

What to watch

  • US FDA decision on CagriSema for obesity, expected by Novo in the fourth quarter.Q4 2026
  • Stomach side effects, reported in 79.6% of CagriSema users versus 39.9% on placebo in an earlier trial.Q4 2026

Educational content only. Not investment advice.

More briefsAll briefs →